Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT03228667
What this trial is testing

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Who this might be right for
Non-Small Cell Lung CancerSmall Cell Lung CancerUrothelial Carcinoma+10 more
ImmunityBio, Inc. 40
Testing effectiveness (Phase 2)Looking for participantsNCT07255404
What this trial is testing

A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer

Who this might be right for
Pancreatic Ductal Adenocarcinoma (PDAC)
BioNTech SE 105
Large-scale testing (Phase 3)Looking for participantsNCT06980272
What this trial is testing

SSGJ-707 in Advanced Non-Small Cell Lung Cancer

Who this might be right for
Advanced Non-Small Cell Lung Cancer
Shenyang Sunshine Pharmaceutical Co., LTD. 420
Testing effectiveness (Phase 2)Active Not RecruitingNCT03260023
What this trial is testing

Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers

Who this might be right for
HPV-Related CarcinomaHPV-Related Cervical CarcinomaHPV-Related Anal Squamous Cell Carcinoma+2 more
Transgene 143
Testing effectiveness (Phase 2)Study completedNCT02643303
What this trial is testing

Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Who this might be right for
Head and Neck Squamous Cell CarcinomaBreast CancerSarcoma+8 more
Ludwig Institute for Cancer Research 58
Testing effectiveness (Phase 2)Looking for participantsNCT06228066
What this trial is testing

Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

Who this might be right for
Small Cell Carcinoma of the BladderHigh Grade Neuroendocrine Tumors of the Urinary Tract
National Cancer Institute (NCI) 45
Testing effectiveness (Phase 2)UnknownNCT04460066
What this trial is testing

Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma.

Who this might be right for
Esophageal Cancer
Lee's Pharmaceutical Limited 70
Early research (Phase 1)Enrolling By InvitationNCT06115642
What this trial is testing

A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors

Who this might be right for
Advanced/Metastatic Malignant Solid Tumors
Shanghai Henlius Biotech 367
Large-scale testing (Phase 3)Looking for participantsNCT07144280
What this trial is testing

Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell CarcinomaNon-Small Cell Lung Cancer MetastaticNon-Small Cell Lung Carcinoma
Pfizer 680
Testing effectiveness (Phase 2)Study completedNCT04121442
What this trial is testing

Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors

Who this might be right for
Solid Tumor, Adult
Buzzard Pharmaceuticals 15
Large-scale testing (Phase 3)Active Not RecruitingNCT06500026
What this trial is testing

A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)

Who this might be right for
Small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 722
Very early researchEnrolling By InvitationNCT07023068
What this trial is testing

⁶⁸Ga-DPA in the Lung Cancer Diagnosis

Who this might be right for
Lung Cancers
Peking Union Medical College Hospital 40
Testing effectiveness (Phase 2)Ended earlyNCT04396535
What this trial is testing

Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer

Who this might be right for
Advanced Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8+5 more
Mayo Clinic 10
Not applicableUnknownNCT04860076
What this trial is testing

Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors

Who this might be right for
MelanomaLung Cancer
Asylia Diagnostics BV 400
Early research (Phase 1)Ended earlyNCT03343613
What this trial is testing

LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors

Who this might be right for
Solid TumorNon Small Cell Lung CancerRenal Cell Carcinoma+1 more
Eli Lilly and Company 60
Early research (Phase 1)Study completedNCT02261220
What this trial is testing

MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
MedImmune LLC 380
Testing effectiveness (Phase 2)Study completedNCT05505825
What this trial is testing

AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer

Who this might be right for
SCLC,Extensive Stage
Akeso 36
Testing effectiveness (Phase 2)Looking for participantsNCT06742424
What this trial is testing

PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC

Who this might be right for
Hepato Cellular Carcinoma (HCC)
West China Hospital 36
Testing effectiveness (Phase 2)Study completedNCT02255097
What this trial is testing

Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)

Who this might be right for
Head and Neck Squamous Cell Carcinoma
Merck Sharp & Dohme LLC 172
Large-scale testing (Phase 3)Study completedNCT02819518
What this trial is testing

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)

Who this might be right for
Triple Negative Breast Cancer (TNBC)
Merck Sharp & Dohme LLC 882
Next Page